It is therefore recommended to monitor tacrolimus blood levels whenever substances which have the potential to alter CYP3A metabolism are used concomitantly and to adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure (see sections 4.2 and 4.4).
34 takroliimuse kontsentratsiooni veres ja korrigeerida vastavalt takroliimuse annust, et säiliks samasugune ekspositsioon (vt lõigud 4. 2 ja 4. 4).